FDA approves bispecific antibody for rare leukaemia

The Food and Drug Administration has given its first approval to a single-agent immunotherapy for cancer – Amgen Inc’s Blincyto (blinatumomab) for the treatment of refractory B-cell precursor acute lymphoblastic leukaemia (ALL).